GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Book Value per Share

Icosavax (Icosavax) Book Value per Share : $4.64 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Icosavax Book Value per Share?

Icosavax's book value per share for the quarter that ended in Sep. 2023 was $4.64.

During the past 12 months, Icosavax's average Book Value Per Share Growth Rate was -18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Icosavax's current price is $15.31. Its book value per share for the quarter that ended in Sep. 2023 was $4.64. Hence, today's PB Ratio of Icosavax is 3.30.

During the past 4 years, the highest P/B Ratio of Icosavax was 5.30. The lowest was 0.38. And the median was 3.22.


Icosavax Book Value per Share Historical Data

The historical data trend for Icosavax's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Book Value per Share Chart

Icosavax Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Book Value per Share
-0.81 -9.28 7.10 5.31

Icosavax Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 5.31 4.84 4.96 4.64

Competitive Comparison of Icosavax's Book Value per Share

For the Biotechnology subindustry, Icosavax's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icosavax's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Icosavax's PB Ratio distribution charts can be found below:

* The bar in red indicates where Icosavax's PB Ratio falls into.



Icosavax Book Value per Share Calculation

Icosavax's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(218.16-0.00)/41.10
=5.31

Icosavax's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(232.38-0.00)/50.09
=4.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Icosavax  (NAS:ICVX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Icosavax Book Value per Share Related Terms

Thank you for viewing the detailed overview of Icosavax's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Icosavax (Icosavax) Business Description

Traded in Other Exchanges
N/A
Address
1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101
Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Executives
Adam K. Simpson director, officer: Chief Executive Officer C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan officer: Chief Medical Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley officer: Chief Business Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo officer: Chief Financial Officer C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman officer: Chief Scientific Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan officer: EVP, Head of Research & Dev. C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu officer: See Remarks 1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson officer: See Remarks 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil director C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver director C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi 10 percent owner 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p. 10 percent owner GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807